Combinatorial Cancer Immunotherapies

被引:87
|
作者
Hellmann, Matthew D. [1 ,2 ]
Friedman, Claire F. [1 ,2 ]
Wolchok, Jedd D. [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Weill Cornell Med Coll, New York, NY USA
来源
TUMOR IMMUNOLOGY | 2016年 / 130卷
关键词
REGULATORY T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; DOUBLET CHEMOTHERAPY; METASTATIC MELANOMA; ANTITUMOR IMMUNITY; PD-1; BLOCKADE; DOUBLE-BLIND; DILATED CARDIOMYOPATHY; NIVOLUMAB ANTI-PD-1; BIOLOGICAL APPROACH;
D O I
10.1016/bs.ai.2015.12.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
T cell checkpoint blockade therapies are revolutionizing the treatment of patients with cancer. Highlighted by the recent success of PD-1 plus CTLA-4 blockade in patients with melanomas, synergistic immunotherapy combinations of modalities represent an important opportunity to improve responses and outcomes for patients. We review the rationale and experience with T cell checkpoint blockade in combination with targeting of other coinhibitory or costimulatory checkpoints, immunomodulatory molecules in the tumor microenvironment, and other anticancer modalities such as vaccines, chemotherapy, and radiation.
引用
收藏
页码:251 / 277
页数:27
相关论文
共 50 条
  • [21] Microbiome and cancer immunotherapies
    Chen, Haoyan
    Zitvogel, Laurence
    Peng, Zhi
    Yin, Xiaochen
    McAllister, Florencia
    CELL REPORTS MEDICINE, 2024, 5 (04)
  • [22] Potentiating cancer immunotherapies
    Nature Biomedical Engineering, 2021, 5 : 1241 - 1242
  • [23] Cellular immunotherapies for cancer
    Hayes, Conall
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (01) : 41 - 57
  • [24] Immunotherapies for Lung Cancer
    Gubens, Matthew A.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (5.5): : 692 - 695
  • [25] High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific In Silico Models of Metastatic Colorectal Cancer
    Kather, Jakob Nikolas
    Charoentong, Pornpimol
    Suarez-Carmona, Meggy
    Herpel, Esther
    Klupp, Fee
    Ulrich, Alexis
    Schneider, Martin
    Zoernig, Inka
    Luedde, Tom
    Jaeger, Dirk
    Poleszczuk, Jan
    Halama, Niels
    CANCER RESEARCH, 2018, 78 (17) : 5155 - 5163
  • [26] Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer
    Joyce V. Lee
    Filomena Housley
    Christina Yau
    Rachel Nakagawa
    Juliane Winkler
    Johanna M. Anttila
    Pauliina M. Munne
    Mariel Savelius
    Kathleen E. Houlahan
    Daniel Van de Mark
    Golzar Hemmati
    Grace A. Hernandez
    Yibing Zhang
    Susan Samson
    Carole Baas
    Marleen Kok
    Laura J. Esserman
    Laura J. van ‘t Veer
    Hope S. Rugo
    Christina Curtis
    Juha Klefström
    Mehrdad Matloubian
    Andrei Goga
    Nature Communications, 13
  • [27] Advancing Cancer Immunotherapies with Nanotechnology
    Lou, Jenny
    Zhang, Li
    Zheng, Gang
    ADVANCED THERAPEUTICS, 2019, 2 (04)
  • [28] Neurotoxicity of novel cancer immunotherapies
    M. D. Willis
    N. P. Robertson
    Journal of Neurology, 2019, 266 : 2087 - 2089
  • [29] Commercialization of cellular immunotherapies for cancer
    Walker, Anthony
    Johnson, Robert
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2016, 44 : 329 - 332
  • [30] Advances in prostate cancer immunotherapies
    Basler, Michael
    Groettrup, Marcus
    DRUGS & AGING, 2007, 24 (03) : 197 - 221